File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection

TitleLansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection
Authors
Issue Date2006
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2006, v. 23 n. 3, p. 421-427 How to Cite?
AbstractAim: To test the efficacy of levofloxacin-based second-line therapy for resistant Helicobacter pylori infection. Methods: One hundred and six patients who failed H. pylori eradication were randomized to receive (i) lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL); or (ii) lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple). Post-treatment H. pylori status was determined by 13C-urea breath test. Results: Intention-to-treat and per-protocol H. pylori eradication rates were 57/60% for the LAL group and 71/76% for the quadruple group respectively. Metronidazole, clarithromycin, amoxicillin and levofloxacin resistance were found in 76%, 71%, 0% and 18% of patients, respectively. Levofloxacin resistance led to treatment failure in the LAL group. For patients with dual resistance to metronidazole and clarithromycin, the eradication rates were 79% in the LAL group (levofloxacin-sensitive) and 65% in the quadruple group (P = 0.34). Conclusion: Lansoprazole, amoxicillin plus levofloxacin second-line therapy is comparable with quadruple therapy in efficacy. Subjects, especially those with dual resistance to metronidazole and clarithromycin, may consider levofloxacin-based therapy for levofloxacin- sensitive strains. © 2006 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/162950
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorGu, Qen_HK
dc.contributor.authorChu, KMen_HK
dc.contributor.authorYee, YKen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorTong, TSMen_HK
dc.contributor.authorChan, AOOen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2012-09-05T05:25:46Z-
dc.date.available2012-09-05T05:25:46Z-
dc.date.issued2006en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2006, v. 23 n. 3, p. 421-427en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162950-
dc.description.abstractAim: To test the efficacy of levofloxacin-based second-line therapy for resistant Helicobacter pylori infection. Methods: One hundred and six patients who failed H. pylori eradication were randomized to receive (i) lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL); or (ii) lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple). Post-treatment H. pylori status was determined by 13C-urea breath test. Results: Intention-to-treat and per-protocol H. pylori eradication rates were 57/60% for the LAL group and 71/76% for the quadruple group respectively. Metronidazole, clarithromycin, amoxicillin and levofloxacin resistance were found in 76%, 71%, 0% and 18% of patients, respectively. Levofloxacin resistance led to treatment failure in the LAL group. For patients with dual resistance to metronidazole and clarithromycin, the eradication rates were 79% in the LAL group (levofloxacin-sensitive) and 65% in the quadruple group (P = 0.34). Conclusion: Lansoprazole, amoxicillin plus levofloxacin second-line therapy is comparable with quadruple therapy in efficacy. Subjects, especially those with dual resistance to metronidazole and clarithromycin, may consider levofloxacin-based therapy for levofloxacin- sensitive strains. © 2006 Blackwell Publishing Ltd.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.-
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAmoxicillin - Therapeutic Useen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAnti-Infective Agents - Therapeutic Useen_US
dc.subject.meshDrug Resistance, Bacterialen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylorien_US
dc.subject.meshHong Kongen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMetronidazole - Therapeutic Useen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOfloxacin - Therapeutic Useen_US
dc.subject.meshOmeprazole - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshOrganometallic Compoundsen_US
dc.subject.meshTetracycline - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infectionen_HK
dc.typeArticleen_HK
dc.identifier.emailChu, KM: chukm@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityChu, KM=rp00435en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1111/j.1365-2036.2006.02764.xen_HK
dc.identifier.pmid16423001-
dc.identifier.scopuseid_2-s2.0-33644929196en_HK
dc.identifier.hkuros114297-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33644929196&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue3en_HK
dc.identifier.spage421en_HK
dc.identifier.epage427en_HK
dc.identifier.isiWOS:000234663900009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridGu, Q=24469982400en_HK
dc.identifier.scopusauthoridChu, KM=7402453538en_HK
dc.identifier.scopusauthoridYee, YK=7004400469en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridTong, TSM=7102587364en_HK
dc.identifier.scopusauthoridChan, AOO=7403167965en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.citeulike467942-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats